Read by QxMD icon Read


Alauldeen Mudhafar Zubair Alqasim, Raji Hussein Al-Hadithi, Aseel Nashaat Al-Khalidi
BACKGROUND: L-asparaginase is chemotherapeutic agent commonly used in treatment of Acute Lymphoblastic Leukemia. Thromboembolic and to a lesser extent bleeding events are serious complications associated with administration of this drug during the induction phase in ALL especially in children resulting from reduced synthesis of proteins such as Antithrombin & fibrinogen. OBJECTIVE: Evaluation of the coagulopathic side effect of L-asparaginase during the induction phase in treatment of ALL in children by measuring fibrinogen levels before & after administration of this drug...
February 1, 2018: Hematology/oncology and Stem Cell Therapy
Dorsa Golestaneh, Jaleh Varshosaz
BACKGROUND: L-asparaginase is a drug of choice in the treatment of Hodgkin's lymphoma and acute lymphoblastic leukemia. Production of its bioconjugates can increase its half-life, stability and decrease its immunogenicity. OBJECTIVE: The aim of the present study was to immobilize this drug on silica nanoparticles by two different cross-linking agents. METHOD: The drug was conjugated to nanoparticles by two cross-linking agents; 1-ethyl-3-(3- dimethylaminopropyl) carboiimide HCl (EDC) or glutaraldehyde...
February 14, 2018: Recent Patents on Nanotechnology
Al Rabayah, S Jaddouh, A Amireh
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
Karthik Bommannan, Man Updesh Singh Sachdeva, Neelam Varma, Parveen Bose, Deepak Bansal
OBJECTIVE: To study the role of mid-induction (day 15) peripheral blood minimal residual disease (PB-MRD) detection in pediatric B- lineage acute lymphoblastic leukemia (B-ALL). DESIGN: Prospective. SETTING: Tertiary-care center. PATIENTS: 40 consecutively-diagnosed treatment-naive, pediatric B-ALL patients. INTERVENTION: National Cancer Institute (NCI) standard risk patients were given three drug induction regimen comprising vincristine, L-asparginase and prednisolone; NCI high-risk patients were supplemented with daunorubicin...
December 15, 2016: Indian Pediatrics
Vishal Sondhi, Aditi Sharma, Manish Taneja, Brijesh Arora, Sripad D Banavali
BACKGROUND: The management of hyperleukocytosis currently involves intensive supportive care for preventing tumor lysis syndrome (TLS)-associated metabolic abnormalities as well as cytoreduction procedures to reduce the white blood cell (WBC) count. These procedures are often equipment-intensive and may not be practised in developing countries with limited resources. Hence, it is not clear what would be the most effective strategy to manage hyperleukocytosis and prevent TLS. PROCEDURE: All children ≤12 years, diagnosed with acute lymphoblastic leukemia (ALL) and hyperleukocytosis (WBC count >100 × 10(9)/l) were administered L-asparginase (L-asp, 6,000 U/m(2), i...
2015: Acta Haematologica
Raheel A Raja, Kjeld Schmiegelow, Birgitte K Albertsen, Kaie Prunsild, Bernward Zeller, Goda Vaitkeviciene, Jonas Abrahamsson, Mats Heyman, Mervi Taskinen, Arja Harila-Saari, Jukka Kanerva, Thomas L Frandsen
L-asparaginase is an important drug in the treatment of childhood acute lymphoblastic leukaemia (ALL). Treatment is associated with several toxicities, including acute pancreatitis. Clinical course, presentation, re-exposure to L-asparginase after pancreatitis and risk of recurrent pancreatitis within an asparaginase-intensive protocol has been poorly reported. Children (1-17 years) on the ongoing Nordic Society of Paediatric Haematology and Oncology (NOPHO) ALL2008 protocol with asparaginase-associated pancreatitis (AAP) diagnosed between 2008 and 2012 were identified through the online NOPHO ALL toxicity registry...
April 2014: British Journal of Haematology
S M Abhayakumar, Samit Purohit, B S Arunakumari, K C Lakshmaiah, L Appaji
L-Asparginase is a frequently used drug in hematological malignancies. Various side effects associated with its use include hypersensitivity, hyperglycemia, hypercoaguability and acute pancreatitis. We describe a rare complication of pancreatic pseudocyst in a 12 year old boy of Acute lymphoblastic leukemia (ALL) treated with MCP-841 protocol (during re-induction phase). Nearing the end of induction i.e. day 25, patient complained of a painful swelling in the epigastrium and left hypochondrium. Investigations revealed a pancreatic pseudocyst for which he underwent cystojejunostomy...
September 2013: Indian Journal of Surgical Oncology
William F Qubty, Anna Mrelashvili, Marc C Patterson
No abstract text is available yet for this article.
April 2015: Journal of Child Neurology
Biswajit Dubashi, Ankit Jain
L-Asparginase is used for remission induction in acute lymphoblastic leukemia. We describe a case of 16-year-old boy who developed cortical venous thrombosis following the administration of L-Asparginase.
April 2012: Journal of Pharmacology & Pharmacotherapeutics
William W Bush, Juliene L Throop, Patricia M McManus, Amy S Kapatkin, Charles H Vite, Tom J Van Winkle
A 5-year-old, castrated male mixed-breed dog was presented for paraparesis, ataxia, hyperesthesia, and thrombocytopenia of 5 months' duration and recurrent seizures during the preceding 2 weeks. Multifocal neurological, ophthalmological, pulmonary, and cardiac diseases were identified. Magnetic resonance imaging and cerebrospinal fluid analysis supported a tentative diagnosis of neoplastic or inflammatory disease. A computed tomography-guided biopsy provided both cytopathological and histopathological evidence of intravascular lymphoma...
January 2003: Journal of the American Animal Hospital Association
José Carlos Jaime-Perez, David Gomez-Almaguer
No abstract text is available yet for this article.
August 2002: Haematologica
T Rodriguez, E Baumgarten, R Fengler, D Soumpasis, G Henze
Nine children of the ALL-REZ BFM 87 and 90 trial received L-Asparginase (L-ASP) as a continuous infusion for 48-72 hs (i.e. 25 therapy cycles). Seven patients had had an allergic reaction towards an i.m. application (i.m., 29 therapy cycles). Two further patients got L-ASP initially as continuous infusion. The i.m. applications were carried out 19 times with Erwinia and 10 times with E. coli-Asparaginase, the continuous infusions 15 times with Erwinia and 10 times with E. coli-Asparaginase. In case of four patients continuous infusions of the same L-ASP type (E...
July 1995: Klinische Pädiatrie
P J Moe
No abstract text is available yet for this article.
April 10, 1971: Tidsskrift for Den Norske Lægeforening: Tidsskrift for Praktisk Medicin, Ny Række
V J Land, W W Sutow, D J Fernbach, D M Lane, T E Williams
No abstract text is available yet for this article.
August 1972: Cancer
Y Inada, S Hirose, M Okada, H Mihama
Immobilized asparaginase was prepared by embedding asparaginase (which is effective for remission in children with leukemia) into fibrin polymer formed by fibrinogen-fibrin conversion in the presence of thrombin. The immobilized asparaginase film did not dissolve in 6 mol/1 urea, suggesting that blood coagulation factor XIII participates in the cross-linking between fibrins and between fibrin and asparaginase.
1975: Enzyme
S Plesnicar, R Merolla, R Golouh, D Micu, G Astaldi
Administration of L-asparaginase may cause remission in a high percentage of acute lymphocytic leukemias and lymphomas, either in experimental animals or in human beings. This enzyme is able to depress immune reactions like lymphocyte blastogenesis and delayed hypersensitivity, and to impair gamma-globulin synthesis. L-asparaginase also has antigenic properties, and may cause the formation of anti-L-asparaginase antibodies. This study reports observations on the effect of L-asparginase on the 7S gamma-globulin levels and on the behaviour of the germinal centers in spleen and lymph nodes...
1976: Acta Vitaminologica et Enzymologica
V L Calich, R G Ferri
No abstract text is available yet for this article.
August 1977: Revista do Hospital Das Clínicas
I D Mutz
Recurrence of childhood acute lymphoblastic leukemia occurs in about 30-50% and indicates irresistable progression of the disease. While systemic (= hematologic) relapse is due to drug resistance of leukemic cells, pharmacologic barriers may be responsible for local relapses as meningeal involvement, leukemic ophthalmopathy or testicular infiltration. L-asparginase seems to be an important component of drug combinations for re-induction therapy for systemic relapse. Following reinduction therapy modification of continuation therapy is necessary...
February 1978: Onkologie
M Yonei, Y Mitsui, Y Iitaka
No abstract text is available yet for this article.
February 15, 1977: Journal of Molecular Biology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"